Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

Abroad (travel likely)RecruitingPHASE4

Conditions

Cytomegalovirus Infections · Infection in Solid Organ Transplant Recipients · Neutropenia · Antiviral Toxicity

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases, Boston, Massachusetts, United States
Contact: Study coordinator (Jennifer K Chow, MD, MS) · Jennifer.Chow@TuftsMedicine.org · 617-636-5244
Contact: Study coordinator (Whitney Perry, MD, MS) · Whitney.Perry@tuftsMedicine.org · 339-368-0047
Contact: Principal Investigator (Jennifer K Chow, MD, MS)

Study leads

Jennifer K Chow, MD, MS
Principal Investigator
Tufts Medical Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.

Cytomegalovirus Infections · Cytomegalovirus Disease · Hematopoietic Stem Cell Transplantation

Abroad (travel likely)RecruitingPHASE4

Beijing, China · Shijiazhuang, China

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Cytomegalovirus Infections · Kidney Transplant Infection · Pancreas Transplant

Abroad (travel likely)RecruitingPHASE3

Madison, United States

Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT

Cytomegalovirus Infections · CMV

Abroad (travel likely)Recruiting

Suzhou, China

Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections

Cytomegalovirus Infection

Abroad (travel likely)RecruitingPHASE3

Paris, France · Paris, France